How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?. (Record no. 583)

MARC details
000 -LEADER
fixed length control field 03021nam a22003137a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 220511s20222022 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0041-1132
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1111/trf.16871 [doi]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 35352362
245 ## - TITLE STATEMENT
Title How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?.
251 ## - Source
Source Transfusion. 2022 Mar 29
252 ## - Abbreviated Source
Abbreviated source Transfusion. 2022 Mar 29
253 ## - Journal Name
Journal name Transfusion
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2022
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2022
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Publication date 2022 Mar 29
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status aheadofprint
266 ## - Date added to catalog
Date added to catalog 2022-05-11
520 ## - SUMMARY, ETC.
Abstract Convalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable. The COVID-19 pandemic revived interest in the use of convalescent plasma. Large observational studies and clinical trials that were executed during the pandemic provided insight into how to use convalescent plasma, whereby high levels of antibodies against the pathogen of interest and administration early within the time course of the disease are critical for optimal therapeutic effect. Several studies have shown outpatient administration of COVID-19 convalescent plasma (CCP) to be both safe and effective, preventing clinical progression in patients when administered within the first week of COVID-19. The United States Food and Drug Administration expanded its emergency use authorization (EUA) to allow for the administration of CCP in an outpatient setting in December 2021, at least for immunocompromised patients or those on immunosuppressive therapy. Outpatient transfusion of CCP and infusion of monoclonal antibody therapies for a highly transmissible infectious disease introduces nuanced challenges related to infection prevention. Drawing on our experiences with the clinical and research use of CCP, we describe the logistical considerations and workflow spanning procurement of qualified products, infrastructure, staffing, transfusion, and associated management of adverse events. The purpose of this description is to facilitate the efforts of others intent on establishing outpatient transfusion programs for CCP and other antibody-based therapies. Copyright © 2022 AABB.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element IN PROCESS -- NOT YET INDEXED
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution Washington Cancer Institute
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Shenoy, Aarthi
790 ## - Authors
All authors Abinante M, Adamski J, Anjan S, Bloch EM, Broderick PB, Cachay ER, Casadevall A, Cruser D, Forthal D, Fukuta Y, Gawad A, Gebo KA, Gerber J, Gniadek TJ, Hanley DF, Heath SL, Huaman MA, Kafka K, Kassaye SG, Lane K, Levine A, Marshall C, McBee N, Meisenberg BR, Metcalf RA, Mosnaim GS, Patel B, Paxton JH, Raval JS, Reisler RB, Shenoy A, Shoham S, Sullivan D, Tobian AAR, Yarava A, Zand M, Ziman A
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1111/trf.16871">https://dx.doi.org/10.1111/trf.16871</a>
Public note https://dx.doi.org/10.1111/trf.16871
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 05/11/2022   35352362 35352362 05/11/2022 05/11/2022 Journal Article

Powered by Koha